title: Anti-r-hirudin antibodies reveal clinical relevance through direct functional inactivation of r-hirudin or prolongation of r-hirudin's plasma halflife.
authors.forename: G
authors.initials: G
authors.lastname: Huhle
authors.forename: V
authors.initials: V
authors.lastname: Liebe
authors.forename: R
authors.initials: R
authors.lastname: Hudek
authors.forename: D L
authors.initials: DL
authors.lastname: Heene
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000097:blood* / Q000494:pharmacology / Q000627:therapeutic use; D000915:Antibody Affinity; D000991:Antithrombins / Q000008:administration & dosage / Q000276:immunology* / Q000493:pharmacokinetics; D005260:Female; D006207:Half-Life; D024764:Hirudin Therapy; D006629:Hirudins / Q000008:administration & dosage / Q000276:immunology* / Q000493:pharmacokinetics; D006801:Humans; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000276:immunology / Q000493:pharmacokinetics; D013921:Thrombocytopenia / Q000139:chemically induced / Q000188:drug therapy
chemical_list: D000911:Antibodies, Monoclonal; D000991:Antithrombins; D006629:Hirudins; D011994:Recombinant Proteins